Extended Data Fig. 8: Genetic inhibition of ACLY or treatment with EVT0185 in MASH-driven HCC selectively enhances tumor-infiltrating B cell populations with minimal impact on other immune cells.
From: ACLY inhibition promotes tumour immunity and suppresses liver cancer
a-b, Immune cell markers expressed in different cell types in a, WT and Acly KO and b, Vehicle and EVT0185-treated mice. c, Top upregulated pathways in B cells in Acly KO or EVT0185-treated mice (spatial transcriptomics analysis). Statistical analysis was performed using Fisher’s Exact test. d and e, Single seq analysis of d, WD-DEN and e, WD-CCl4 mouse livers showing top upregulated pathways in B cells. Statistical analysis was performed using a one-sided hypergeometric test (enrichGO); p-values adjusted by Benjamini-Hochberg. f, Cxcl13 mRNA expression analyzed from publicly available RNA-seq dataset in WT and Acly KO DEN tumors cultured in vitro (GSE223966)10. Boxplot lines represent the first quartile, median, and third quartile. Whiskers connect the minimum and maximum values. Significance was ascertained by an unpaired two-tailed t-test between Acly KO vs WT (n = 4 hepatocellular carcinoma cell lines derived from DEN-induced tumors in Aclyf/f mice).
